OP0059 MAVRILIMUMAB (ANTI GM-CSF RECEPTOR Α MONOCLONAL ANTIBODY) REDUCES RISK OF FLARE AND INCREASES SUSTAINED REMISSION IN A PHASE 2 TRIAL OF PATIENTS WITH GIANT CELL ARTERITIS
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.1915
Abstract: T helper (Th)1 and Th17 lymphocytes play a role in the pathogenesis of giant cell arteritis (GCA). Current treatments primarily target the Th17 axis, possibly leaving residual Th1 activity. Granulocyte macrophage colony stimulating factor (GM-CSF),… read more here.
Keywords: placebo; kiniksa; kiniksa pharmaceuticals; week ... See more keywords
Comparison of the efficacy and safety of tofacitinib and mavrilimumab in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of clinical pharmacology and therapeutics"
DOI: 10.5414/cp203979
Abstract: OBJECTIVES The relative efficacy and safety of tofacitinib and mavrilimumab were assessed in patients with rheumatoid arthritis (RA) presenting an inadequate response to disease-modifying antirheumatic drugs (DMARDs). MATERIALS AND METHODS We performed a Bayesian network… read more here.
Keywords: efficacy safety; mtx; safety tofacitinib; tofacitinib mavrilimumab ... See more keywords